Epilepsy and PPD just the beginning. SAGE has the potential to be a huge player in this space years from now - provided they don't get purchased before that. Reminds me of Vertex back in the late 90's (now a 30 Billion dollar company).
Link on yahoo.
Buying on a dip after an earnings beat and reaffirmed guidance, that's how it's done.
The SPA from the FDA received last week places them one step closer to drug approval with a therapy that has wide applications in CNS disorders besides SRSE. $150 is the current target. Assuming SAGE doesn't get acquired, they could easy achieve $350-400 on a pre-split basis with 3-4 indications for SAGE-547. SE provides 4 different grade levels alone, add to that PPD. $$$
Great post. Agree on all your points. Typically I keep tights stops, but FMI is a different story. No doubt I will be able to sell it for more than $50, so I'm happy to buy at these prices while people play games with a couple million shares that are available to trade. Bottom line, if Roche and major institutions are holding 98% of the outstanding shares they'll be able to engineer the mother of all short squeezes to move this over $50. Roche will get there money back and then some. You can count on that.
Interesting, so you think Roche will come knocking for the remaining shares at some point? Provide a little more context on the Roche/Illumina deal and how that might play out here. Thanks.
I know the intent was to treat homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH), but I also noticed "clinical atherosclerotic cardiovascular disease (ASCVD)" added as an indication as well.
That would certainly broaden the patient pool significantly as determination of ASCVD would be a more subjective clinical measure than a specific genetic test for one of the other two indications. This would seem to be a huge advantage over Praluent. Any cardiologists here to comment?
"Repatha is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C; and as an adjunct to diet and other LDL-lowering therapies for the treatment of patients with homozygous familial hypercholesterolemia (HoFH), who require additional lowering of LDL-C. The effect of Repatha on cardiovascular morbidity and mortality has not been determined."